
    
      This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute
      pneumonia in non-small cell lung cancer with bulky tumor.

      All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP),
      each of 1 day's duration, combined with split-course thoracic radiotherapy of 51 Gy/17
      fractions and 15 Gy/5 fractions administered in the first and second courses, respectively,
      with one-month break.In the consolidation arm, patients were further treated with
      subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation
      to 2 months after the end of radiation. Toxicities will be graded according to CTCAE v. 4.0.
    
  